Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have earned a consensus rating of “Moderate Buy” from the ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

Editas Medicine EDIT incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus ...

Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia. When the normal DNA sequence in an individual changes or mutates it can cause ...

In fact, it has already done so. Last year, it got the nod for Casgevy, a gene-editing treatment for two rare blood disorders ...

Beta-thalassemia is a rare blood disorder caused by a genetic defect in hemoglobin. Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered ...

For more than a year, public sector hospitals nationwide, including those in Delhi, have been facing an acute shortage of ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know ...

It's evaluating the experimental therapy in late-stage studies as a treatment for sickle cell disease and in early-stage studies targeting beta-thalassemia. The company believes that reni-cel ...

Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease.

Agios Pharmaceuticals (AGIO) announced that new data on mitapivat and tebapivat, AG-946, the company’s PK activators, will be featured in ...